Lumida
/MLYS
⌘K
Mineralys Therapeutics Inc

Mineralys Therapeutics Inc

MLYS
$28.20USD-3.75%-1.10 today

MARKET CAP

2.5B

P/E (TTM)

FWD P/E

DAY RANGE

$28 – $30

52W RANGE

$22
$48

AI Summary

Stalk
Buy NowMedium

MLYS appears in a Stage 2 recovery after a late-cycle capitulation; short-term EMAs have crossed above the 50 SMA signaling nascent bullish momentum, yet the 200 SMA remains overhead and acted as resistance in mid-September. A series of higher lows supports a base formation, giving a medium-term bullish bias against a bearish long-term trend. Execution is warranted on a pullback into the rising EMAs for continuation participation.

  • Cash on hand of $661M plus $500M credit facility extends runway to 2028.
  • Lorundrostat Phase II data show significant blood pressure drop and low hyperkalemia.
  • Q2 EPS of -$2.85 versus -$0.55 estimate indicates deteriorating earnings quality.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICTREND
Sales, Adj.
YoY %
P / Sales
EV / Sales
Gross Profit, Adj.
YoY %
Margin %
EV / Gross Profit
EBITDA, Adj.
YoY %
Margin %
EV / EBITDA
EBIT
YoY %
Margin %
EV / EBIT
Net Income
YoY %
Net Margin
EPS (GAAP)
YoY %